{{Drugbox
| drug_name = 
| IUPAC_name = 8-Bromo-1-methyl-6-(pyridin-2-yl)-4''H''-[1,2,4]triazolo[4,3-''a''][1,4]benzodiazepine
| image = Pyrazolam structure.svg
| width = 185

<!-- Clinical data -->
| tradename = 
| pregnancy_category= 
| legal_AU = S9
| legal_CA = Schedule IV
| legal_status = 
| routes_of_administration = [[oral administration|Oral]], [[sublingual administration|Sublingual]], [[rectal]]

<!-- Pharmacokinetic data -->
| bioavailability  = 
| protein_bound = 
| metabolism  = 
| elimination_half-life = 17 hours
| excretion =

<!-- Identifiers -->
| CAS_number = 39243-02-2
| ATCvet = 
| ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_suffix  = 
| PubChem = 12562545
| ChemSpiderID = 15417688
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 8LH16383PK
| ChEMBL = 3246831

<!-- Chemical data -->
| C=16 | H=12 | Br=1 | N=5
| molecular_weight  = 354.204 g/mol
| smiles = CC1=NN=C2CN=C(C3=NC=CC=C3)C3=CC(Br)=CC=C3N12
| StdInChI = 1S/C16H12BrN5/c1-10-20-21-15-9-19-16(13-4-2-3-7-18-13)12-8-11(17)5-6-14(12)22(10)15/h2-8H,9H2,1H3
| StdInChIKey = BGRWSFIQQPVEML-UHFFFAOYSA-N
}}

'''Pyrazolam''' is a [[benzodiazepine]] derivative originally developed by a team led by [[Leo Sternbach]] at [[Hoffman-La Roche]] in the 1970s,<ref>{{Cite patent | country=US |number= 3954728 | title =Preparation of triazolo benzodiazepines and novel compounds}}</ref> and subsequently "rediscovered" and sold as a [[designer drug]] starting in 2012.<ref name="Moosmann">{{cite journal | url=https://link.springer.com/article/10.1007%2Fs11419-013-0187-4 | date=July 2013 | first1=B. | first2=M. | first4=S. | last1=Moosmann | title=Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine | last2=Hutter | last3=Huppertz | first3=L. M. | last4=Ferlaino | last5=Redlingshöfer | first5=L. | last6=Auwärter | first6=V. | journal=Forensic Toxicology | volume=31 | issue=2 | pages=263–271 | doi=10.1007/s11419-013-0187-4}}</ref><ref>{{cite journal | author1=Bjoern Moosmann | title=Designer benzodiazepines: A new challenge | date=June 2015 | author2=Leslie A King | author3=Volker Auwärter | journal=World Psychiatry | volume=14 | issue=2 | pages=248 | doi=10.1002/wps.20236 | pmid=26043347 | PMC=4471986}}</ref><ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.2003/abstract | title=Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays |author1=Madeleine Pettersson Bergstrand |author2=Anders Helander |author3=Therese Hansson |author4=Olof Beck | journal=Drug Testing and Analysis | date=2016 | doi=10.1002/dta.2003 | pmid=27366870}}</ref><ref>{{cite journal|first1=Gudrun|last1=Høiseth|first2=Silja Skogstad|last2=Tuv|first3=Ritva|last3=Karinen|title=Blood concentrations of new designer benzodiazepines in forensic cases|url=http://www.sciencedirect.com/science/article/pii/S0379073816304121|journal=Forensic Science International|doi=10.1016/j.forsciint.2016.09.006|date=2016|volume=268|pages=35–38|pmid=27685473}}</ref>

Pyrazolam has structural similarities to [[alprazolam]]<ref>{{cite journal | author1=Hester Jr | first1=J. B. | url=http://pubs.acs.org/doi/abs/10.1021/jm00293a015 | title=6-Phenyl-4H-s-triazolo[4,3-a][l,4]benzodiazepines Which Have Central Nervous System Depressant Activity | last2=Rudzik | first2=A. D. | last3=Kamdar | first3=B. V. | journal=J. Med. Chem. | date=November 1971 | volume=14 | issue=11 | pages=1078–1081 | doi=10.1021/jm00293a015 | pmid=5165540}}</ref> and [[bromazepam]]. Unlike other benzodiazepines, pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine.<ref name=Moosmann/><ref>[https://www.uniklinik-freiburg.de/fileadmin/mediapool/08_institute/rechtsmedizin/pdf/Poster2013/Mossmann_DPHG2013.pdf Characterization of the designer benzodiazepines pyrazolam and flubromazepam and study on their detectability in human serum and urine samples], B. Moosmann, M. Hutter, L. M. Huppertz and V. Auwärter</ref> It is most selective for the α<sub>2</sub> and α<sub>3</sub> subtypes of the [[GABAA receptor|GABA<sub>A</sub> receptor]].<ref>{{cite journal | title=6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity | journal=Journal of Medicinal Chemistry | date=November 1979 | volume=22 | issue=11 | pages=1390–1398 | doi=10.1021/jm00197a021 | first1=J. B. | last1=Hester | url=http://pubs.acs.org/doi/abs/10.1021/jm00197a021 | last2=von Voigtlander | first2=P. | pmid=42799}}</ref>

== Legal Status ==

=== United Kingdom ===
In the UK, pyrazolam has been classified as a&nbsp;[[Drugs controlled by the UK Misuse of Drugs Act|Class C drug]]&nbsp;by section 5 of the May 2017 amendment to&nbsp;[[Misuse of Drugs Act 1971|The Misuse of Drugs Act 1971]]&nbsp;along with several other designer benzodiazepine drugs.<ref>{{Cite web|url=http://www.legislation.gov.uk/uksi/2017/634/contents/made|title=The Misuse of Drugs Act 1971 (Amendment) Order&nbsp;2017|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>

==See also==
* [[List of benzodiazepine designer drugs]]

==References==
{{reflist}}

{{Benzodiazepines}}
{{GABAAR PAMs}}

[[Category:Triazolobenzodiazepines]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Designer drugs]]
[[Category:Pyridines]]
[[Category:Bromoarenes]]